



November 1, 2023

8:00 am to 12:00 pm Arizona Time

Sonora G

8:00 - 8:03am: **Welcome**

Samantha Masterson, President and CEO, MGFA

8:03 - 8:06am: **Introduction of Keynote Speaker**

Dr. Ali Habib, Steering Committee Chair

8:06 - 8:41am: **Unraveling the puzzle: Game-changing Biomarker Development in Myasthenia Gravis**

Dr. Anna Punga, Keynote Speaker

8:41 - 8:51am: Q&A

8:51 - 8:53am: **Introduction to Biomarkers and Hot Topics**

Dr. Ali Habib, Steering Committee Chair

8:53 - 9:00am: INVESTIGATING IMMUNOLOGICAL PROFILES OF THYMUS IN ACHR-MG BY SCRNA-SEQ

Dr. Yingkai (Kevin) Li

9:00 – 9:07am: A PHASE 0 STUDY ESTABLISHING A ROBUST T CELL ASSAY FOR THE FIRST IN HUMAN TRIAL OF CNP-106 FOR GENERALIZED ACHR+ MG

Dr. Samantha Genardi

9:07 - 9:14am: RACIAL DISPARITIES IN ACUTE CARE UTILIZATION OUTCOMES AMONG THOSE WITH MYASTHENIA GRAVIS

Dr. Pushpa Narayanaswami

9:14 - 9:21am: DIFFERENCES IN CLINICAL CARE BETWEEN BLACK AND NON-BLACK PATIENTS WITH GMG RECEIVING ECULIZUMAB IN THE UNITED STATES

Dr. Adrian Kielhorn

9:21 – 9:28am: PREVALENCE AND DIVERSITY OF MYASTHENIA GRAVIS IN THE UNITED STATES: A CROSS-SECTIONAL STUDY OF THE NIH ALL OF US RESEARCH PROGRAM DATABASE

Dr. Bhaskar Roy

9:28 - 9:35am: Q&A

9:35 - 10:05am: **Break - Visit posters and sponsor tables**

10:05 - 10:07am: **Introduction to Clinical Trials**

Dr. Diana Castro (Steering Committee)

10:07 - 10:14am: ACHIEVEMENT OF MINIMAL SYMPTOM EXPRESSION IN ACETYLCHOLINE-RECEPTOR ANTIBODY-POSITIVE PARTICIPANTS WITH GENERALIZED MYASTHENIA GRAVIS AND EFFECT ON DISEASE-SPECIFIC MEASURES IN ADAPT/ADAPT+ STUDIES

Dr. James Howard

10:14 - 10:21am: MG-ADL AND QMG SCORES OVER TIME IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS: POST-HOC ANALYSIS OF MYCARING AND OPEN-LABEL STUDIES

Dr. Vera Brill

10:21 - 10:28am: ZILUCOPLAN IN PEDIATRIC PATIENTS WITH ACETYLCHOLINE RECEPTOR AUTOANTIBODY-POSITIVE GENERALIZED MYASTHENIA GRAVIS: ZIMYG (MG0014) AND ZIMYG+ (MG0015) CLINICAL STUDY DESIGNS

Dr. Sigrid Nilius

10:28 - 10:35am: EARLY RESPONDERS WITH ZILUCOPLAN: AN INTERIM ANALYSIS OF RAISE-XT IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS

Dr. Miriam Freimer

10:35 - 10:42am: ANTIGEN-SPECIFIC IMMUNE THERAPY (CNP-106) FOR TREATMENT OF GENERALIZED MYASTHENIA GRAVIS: RATIONALE AND DESIGN OF FIRST-IN-HUMAN RANDOMIZED CONTROLLED TRIAL

Dr. Richard Nowak

10:42 – 10:49am: SUBCUTANEOUS EFGARTIGIMOD PH20 TREATMENT IN PARTICIPANTS WITH GENERALIZED MYASTHENIA GRAVIS IN ADAPT-SC+: INTERIM ANALYSES ON QUALITY OF LIFE, EFFICACY, TOLERABILITY, AND LONG-TERM SAFETY

Dr. Tuan Vu

10:49 – 10:56am: Q&A

10:56 – 10:58am: **Introduction to General Practice**

Dr. Neelam Goyal (Steering Committee)

10:58 – 11:06am: MGFA Global MG Patient Registry Update

Renee Willmon of Alira Health

11:06 – 11:13am: NATIONAL TRENDS IN THE UTILIZATION OF THYMECTOMY FOR MYASTHENIA GRAVIS

Dr. Jennifer Morganroth

11:13 – 11:20am: MEASURING ADVERSE EVENT BURDEN IN MYASTHENIA GRAVIS: RETROSPECTIVE

VALIDATION OF THE ADVERSE EVENT UNIT (AEU) WITH MGTX TRIAL DATA
Dr. Michael Hehir

11:20- 11:27am: MANAGEMENT OF MYASTHENIA GRAVIS AROUND THE GLOBE: CONSENSUS
GUIDELINES VS REALITIES OF PRACTICE
Dr. Julia Greenberg

11:27 - 11:34am: NEAR FIBER EMG: A NEW WAY TO ASSESS MOTOR UNIT INSTABILITY AND
ELECTROPHYSIOLOGICAL TEMPORAL DISPERSION
Dr. Daniel Stashuk

11:34 - 11:41am: MGNATION: A REAL WORLD STUDY CAPTURING PATIENT, HEALTHCARE
PROFESSIONAL AND CAREGIVER PERSPECTIVES
Dr. Pushpa Narayanaswami

11:41 - 11:48am: RESULTS OF THE MGNET ADAPTING DISEASE-SPECIFIC OUTCOME MEASURES PILOT
TRIAL FOR TELEHEALTH IN MYASTHENIA GRAVIS (ADAPT-TELEMG)
Dr. Amanda Guidon

11:48 – 11:55am: Q&A

11:55 – 12:00pm: **Thank you's**
Samantha Masterson, President and CEO, MGFA

*Session speakers and titles subject to change